Morrow, L <br/><br/>
Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Jan 2011 
 - 75-80 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1326.2010.01322.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Area Under Curve<br/>Diabetes Mellitus, Type 2--blood<br/>Drug Interactions<br/>Drug Therapy, Combination<br/>Female<br/>Glucagon-Like Peptide 1--analogs & derivatives<br/>Humans<br/>Hypoglycemic Agents--pharmacokinetics<br/>Insulin--administration & dosage<br/>Insulin Detemir<br/>Insulin, Long-Acting<br/>Liraglutide<br/>Male<br/>Middle Aged<br/>Treatment Outcome